Renalytix AI logo

RENX - Renalytix AI Share Price

515p 55.0  12.0%

Last Trade - 3:57pm

Sector
Technology
Size
Small Cap
Market Cap £331.3m
Enterprise Value £315.7m
Revenue £78.6k
Position in Universe 660th / 1800
Bullish
Bearish
Unlock RENX Revenue
Momentum
Relative Strength (%)
1m -5.61%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -30.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 0.95 18.2
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2019, RenalytixAi PLC revenues increased from $0K to $105K. Net lossincreased 50% to $3.8M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsAdministrative expenses increase of 59% to $4.5M (expense).Basic Earnings per Share excluding Extraordinary Itemsdecreased from -$0.05 to -$0.06.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for RENX
Graphical History

Revenue

RENX Revenue Unlock RENX Revenue

Net Income

RENX Net Income Unlock RENX Revenue

Normalised EPS

RENX Normalised EPS Unlock RENX Revenue

PE Ratio Range

RENX PE Ratio Range Unlock RENX Revenue

Dividend Yield Range

RENX Dividend Yield Range Unlock RENX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RENX EPS Forecasts Unlock RENX Revenue
Profile Summary

Renalytix AI plc is an artificial intelligence-enabled in vitro diagnostics company. The Company’s diagnostic platform, KidneyIntelX, employs artificial intelligence-enabled algorithm that combines data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record (HER) systems, to generate a patient risk score. Its patient risk score enables prediction of progressive kidney function decline in chronic kidney disease (CKD), allowing physicians and healthcare systems to manage the allocation of treatments and clinical resources to patients. KidneyIntelX provides a reportable patient risk score integrated with specific guideline-driven clinical recommendations designed to manage patient treatment and compliance outcomes. The KidneyIntelX risk score is tied to specific clinical guideline recommendations developed by the healthcare system, health insurance providers or practice groups.

Directors
Last Annual June 30th, 2019
Last Interim December 31st, 2019
Incorporated March 15, 2018
Public Since November 6, 2018
No. of Shareholders: n/a
No. of Employees: n/a
Sector Technology
Industry Software & IT Services
Index FTSE Aim All Share , FTSE Aim 100 ,
Exchange London Stock Exchange (AIM)
Shares in Issue 72,029,634
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RENX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RENX
Upcoming Events for RENX
Monday 7th December, 2020
Renalytix AI PLC Annual Shareholders Meeting
Frequently Asked Questions for Renalytix AI
What is the Renalytix AI share price?

As of 3:57pm, shares in Renalytix AI are trading at 515p, giving the company a market capitalisation of £331.3m. This share price information is delayed by 15 minutes.

How has the Renalytix AI share price performed this year?

Shares in Renalytix AI are currently trading at 515p and the price has moved by 66.67% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Renalytix AI price has moved by 90.42% over the past year.

What are the analyst and broker recommendations for Renalytix AI?

Of the analysts with advisory recommendations for Renalytix AI, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Renalytix AI is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Renalytix AI next release its financial results?

Renalytix AI is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Renalytix AI dividend yield?

Renalytix AI does not currently pay a dividend.

Does Renalytix AI pay a dividend?

Renalytix AI does not currently pay a dividend.

When does Renalytix AI next pay dividends?

Renalytix AI does not currently pay a dividend.

How do I buy Renalytix AI shares?

To buy shares in Renalytix AI you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Renalytix AI?

Shares in Renalytix AI are currently trading at 515p, giving the company a market capitalisation of £331.3m.

Where are Renalytix AI shares listed? Where are Renalytix AI shares listed?

Here are the trading details for Renalytix AI:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: RENX
What kind of share is Renalytix AI?

Based on an overall assessment of its quality, value and momentum, Renalytix AI is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Renalytix AI share price forecast 2020?

Shares in Renalytix AI are currently priced at 515p. At that level they are trading at 0.261% discount to the analyst consensus target price of 516.35.

Analysts covering Renalytix AI currently have a consensus Earnings Per Share (EPS) forecast of -0.1808939311 for the next financial year.

How can I tell whether the Renalytix AI share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Renalytix AI. Over the past six months, the relative strength of its shares against the market has been 2.35%. At the current price of 515p, shares in Renalytix AI are trading at 6.95% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Renalytix AI PE Ratio?

We were not able to find PE ratio data for Renalytix AI.

Who are the key directors of Renalytix AI?

We were unable to find the directors for Renalytix AI.

Who are the major shareholders of Renalytix AI?

Here are the top five shareholders of Renalytix AI based on the size of their shareholding:

Mills (Christopher Harwood Bernard) Individual Investor
Percentage owned: 12.77% (9.20m shares)
Icahn School of Medicine at Mount Sinai Corporation
Percentage owned: 12.29% (8.85m shares)
Lombard Odier Asset Management (Europe) Ltd Investment Advisor
Percentage owned: 4.1% (2.95m shares)
McCullough (James) Individual Investor
Percentage owned: 3.98% (2.87m shares)
Polar Capital LLP Investment Advisor/Hedge Fund
Percentage owned: 3.8% (2.73m shares)
Similar to RENX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.